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Abstract 
Parkinson’s disease is the second most 
common neurodegenerative disease, 
following Alzheimer’s disease. It is 
characterized by a series of motor 
symptoms, however, there are multiple 
non-motor symptoms that also occur. At 
the microscopic level, there is a 
degeneration of dopaminergic receptors in 
the neurons, and also an accumulation of 
the misfolded protein alpha-synuclein, 
throughout the body. The majority of the 
depletion of these dopaminergic neurons 
occurs in the substantia nigra. Recently, 
research has pointed to a change in the 
environment of the gut microbiota as being 
responsible for the development of 
Parkinson’s disease. There is bidirectional 
communication between the gut and the 
brain; this is termed the gut—brain axis. 
When the gut microbiota environment is 
altered, the patient is susceptible to several 
issues, including inflammation. When the 
microbiome is altered, it has also been 
found that alpha-synuclein will aggregate. 
Parkinson’s is typically instigated by an 
external trigger, however, it has recently 
been found that a change in the gut 
microbiome may be enough of a trigger. 
Even if the cause of Parkinson’s disease is 
not found to reside within the discovery of 
the gut-brain axis, there is much potential 
for future treatments and therapies within 
it.  
Introduction 
Neurodegenerative diseases indicate that 
there is a part of the brain that is losing its 
ability to function. The two most common 
neurodegenerative diseases include 
Alzheimer’s and Parkinson’s disease. 
Parkinson’s disease, for example, involves 
losing motor functions and developing 
symptoms such as tremors, bradykinesia 
and rigidity. According to Ganjavi and 
MacDonald, around 3% of the population 
over 65 currently suffers from Parkinson’s 
disease. These large numbers make 
Parkinson’s disease (PD) an important area 
to study (2015). Caputi and Giron go on to 
state that the number of those suffering 
from PD is expected to double in the next 
15 years and that this will be due to the 
lengthening of the average lifespan. They 
call it a “paradoxical effect”. PD is believed 
to be due to the accumulation of alpha-
synuclein and deterioration of 
dopaminergic neurons, specifically in the 
substantia nigra in the brain, however, the 
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exact epidemiology is currently uncertain 
(2018).  
 
This protein (alpha synuclein) will misfold 
and aggregate, which is then called a Lewy 
Body, and is what leads to the typical 
symptoms that one experiences when 
suffering from Parkinson’s disease. Also, the 
degeneration of dopaminergic neurons, 
especially in the substantia nigra, leads to 
the development of these motor deficit 
symptoms (Ganjavi and MacDonald, 2015).  
 
Due to the degeneration of dopaminergic 
neurons in the CNS, a common and 
effective treatment has been to provide 
excess dopamine, in the form of L-DOPA, to 
the patient. L-DOPA is administered to 
these patients because it is the precursor to 
dopamine and it can cross the blood brain 
barrier. The blood brain barrier is designed 
to protect the brain from substances that 
are not intended to affect the CNS, so 
getting drugs to cross it can be a challenge. 
When L-DOPA crosses the blood brain 
barrier, it is able to be converted to 
dopamine and thus will be able to have an 
effect on the dopaminergic neurons in the 
synapses.  
 
During the first stages of Parkinson’s 
development, this treatment works well. As 
the disease progresses, however, the 
efficacy has been seen to decrease. This is 
because the number of receptors present is 
diminished, so it does not really matter how 
much one floods the system with L-DOPA, 
there are not enough receptors to have a 
noticeable response (Varanese, et al., 
2010).  
 
While many people immediately think of 
the visible motor symptoms associated with 
Parkinson’s, there are many non-motor 
symptoms that are just as prevalent. 
Because these aren’t seen immediately 
when observing a patient, they are slower 
to be treated. Olfactory, Gastrointestinal, 
cardiovascular, and urogenital systems are 
some of the regions that are known to be 
affected by Parkinson’s disease. Recently, it 
has been made evident that other nervous 
systems in one’s body are affected by PD – 
specifically the autonomic and enteric 
nervous systems (Mulak & Bonaz, 2015). 
Some non-motor symptoms can include 
anxiety, depression, GI issues, sleep 
disturbances, and an overall decrease in 
one’s quality of life. According to Ganjavi 
and MacDonald, these non-motor 
disturbances have been more prevalent 
with regard to hospitalization compared 
with motor issues.  
 
Anxiety and depression are two of the most 
prevalent non-motor disturbances that 
patients experience. It has been found that 
20-50% of patients with PD suffer from 
anxiety in some form, and 50% experience 
depression. Anxiety is actually seen before 
the major motor deficits in most patients 
(2015).  
 
Dopamine therapy has also been used to 
treat anxiety, in addition to the motor 
symptoms, however, some researchers 
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question its efficacy. Some explain that 
dopamine aides in the treatment of anxiety, 
but most argue that dopamine actually 
increases the anxiety that most people 
experience (Ganjavi and MacDonald, 2015). 
Studies many years ago indicated that the L-
DOPA treatment for PD also had an effect 
on patient’s mood. They used this 
observation to explain that depression 
could be treated along with the motor 
issues. However, there have not been 
studies performed since then to directly 
indicate that the current treatment method 
can be applied to one’s mental health. The 
data obtained have not been statistically 
significant.  
 
Some patients have indicated that L-DOPA 
has improved their anxiety, however, 
researchers have come to the conclusion 
that this is an indirect treatment. Many 
patients are anxious due to their motor 
symptoms, and the L-DOPA therapy reduces 
the deficits that they observe. This, 
therefore, will lead to a decrease in anxiety. 
This happens in a cyclic pattern, however. 
When the patient takes their prescribed 
drug, their symptoms lessen. Then, as the 
drug wears off toward the end of its cycle, 
the symptoms begin to reappear, and in 
turn, the anxious symptoms accompany 
them. If the L-DOPA therapy could become 
more constant, then perhaps the associated 
anxiety could become more constant as 
well (Jaunaris and Eskow, 2011).  
 
Other common non-motor symptoms that 
are experienced by those with PD include 
psychosis and dementia. They are often 
seen in these patients because they have a 
similar pathological development. Non-
motor symptoms are often overlooked 
during consultations because it is not 
immediately understood if they are 
symptoms of the disease directly, or if they 
are a side effect of the medication the 
patients are taking (Varanese, et al., 2010).  
 
One of the most recent theories pertaining 
to Parkinson’s Disease involves the gut-
brain axis’s role on the development of it. 
Mulak and Bonaz explain that PD consists of 
the involvement of the central, autonomic, 
and enteric nervous systems. They state 
that the microbiome in the gut has been 
found to have an impact on neuronal 
activity. Communication happens between 
the gut and the brain, and this 
communication is not limited solely to 
diseased patients. It happens continuously 
in all people, and it happens bidirectionally 
(2015).  
 
Caputi and Giron explain that the 
bidirectionality indicates that there is 
crosstalk leading to issues with the central 
nervous system (CNS) as well as the gut. 
These symptoms include gastrointestinal 
disorders, decreases in hormone 
concentrations, inflammatory diseases, and 
“stress induced GI dysfunction” (2018). A 
diagnosis of Parkinson’s may be preceded 
or followed by a variety of GI symptoms. 
The severity of PD may be directly related 
to the severity of the GI symptoms. Around 
80% of people living with PD display GI 
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disorders, such as constipation, dysphagia, 
irritable bowel syndrome, nausea, and 
hypersalivation. The prevalence of GI 
disorders in people with PD either indicate 
that having PD predisposes one to GI 
disorders, or that GI disorders are part of 
the cause of PD (Mulak and Bonaz, 2015).  
 
Constipation has been observed as the 
most prevalent GI issue in PD patients 
before they are actually diagnosed with 
Parkinson’s. It is developed many years 
before any of the initial motor symptoms 
appear. Obviously, constipation does not 
always indicate that one will develop 
Parkinson’s disease, but this is an 
interesting fact that could be useful in the 
future for earlier diagnosis of PD (Caputi 
and Giron, 2018). Constipation also needs 
to be managed in patients because as PD 
develops, it can decrease the absorption of 
L-DOPA from the bowels. This is especially 
prevalent as the patient progresses to late 
stage PD (Varanese, et al., 2010). 
 
It has been hypothesized that 
neurodegenerative diseases begin in the 
gut and travel to one’s brain. This is where 
research is currently moving. The Enteric 
Nervous System (ENS) is broken down into 
four main levels. The first consisting of the 
neurons – myenteric, submucosal plexi, 
enteric glial cells, and reflexes such as 
peristalsis(Mulak and Bonaz, 2015). The 
neurons in this level communicate directly 
with the microbiome in the gut, which is 
why changes in the GI tract are detected by 
the ENS. The intertwining of microbiota and 
neurons is what has driven researchers to 
pursue the effects of gut environment 
changes on the brain, specifically in 
neurodegenerative diseases. The 
connectedness of these two factors could 
be where PD actually develops, but it could 
also signify a new course of action to treat 
this disease – as well as many other 
diseases. There is much to be learned from 
this rather new information; in fact, the gut 
microbiome is actually beginning to be 
referred to as its own organ or system 
(Caputi and Giron, 2018).  
 
The next level of the ENS consists of 
prevertebral ganglia that regulate visceral 
reflexes, and the third level consists of the 
autonomic nervous system from the spinal 
cord and the brain stem. The fourth level 
consists of higher functions coming from 
the cortical regions. These regions include 
areas such as the basal ganglia, and the 
information travels down the brainstem. 
This is important because mechanisms that 
control the local enteric reflexes, as well as 
neuronal control, exist here. The GI tract is 
not able to function normally or optimally 
when these mechanisms are altered (Mulak 
and Bonaz, 2015).  
 
The composition of the gut microbiota 
remains relatively constant throughout life. 
There are a few instances that will lead to 
the environment of the gut being altered. 
These include taking antibiotics, changing 
one’s diet or lifestyle, and fighting an illness 
or disease. Depending on the issue that one 
is facing, the microbiome may return to 
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normal rather quickly, or the recovery may 
be prolonged. In some instances, the 
environment of the gut may never fully 
return to normal, leaving its host 
susceptible to a wide variety of issues. 
While steps may be taken to avoid this in 
young, strong adults, it is more difficult to 
prevent the weakening of the 
gastrointestinal environment as one ages. 
People with Parkinson’s Disease have been 
found to have an altered composition of 
their gut microbiota, as well as a noticeably 
higher rate of developing Helicobacter 
pylori infections. This bacterium is the most 
prevalent factor in typical gastrointestinal 
disturbances, such as peptic ulcer disease, 
active chronic gastritis, and gastric 
adenocarcinoma (Caputi and Giron, 2018).  
 
While the GI symptoms that are 
experienced with PD may not always be as 
cut and dry as researchers would like, one 
thing that is constant among those suffering 
with PD is the accumulation of misfolded 
alpha synuclein. This protein has been 
found to accumulate in olfactory bulbs, as 
well as the submucosal and mucosal plexi 
mentioned above. The accumulation of this 
protein occurs from the esophagus 
throughout the entire GI tract, ending at 
the rectum. It is believed that alpha 
synuclein is able to accumulate due to leaky 
gut syndrome (increased permeability of 
the gastrointestinal tract). The beginning of 
this accumulation may begin in the 
olfactory bulbs or in the ENS. It is currently 
unknown whether it travels in a retrograde 
fashion from ENS to CNS, or if it travels 
from CNS to ENS, but it has been found to 
be instigated by exposure to some toxin 
(Samson, et al., 2016). One environmental 
toxin that has been shown to cause PD – 
like symptoms in mice is the pesticide 
rotenone. When mice are exposed to this 
pesticide, they begin to develop Parkinson’s 
symptoms, as well as a GI environment 
changes resembling those with PD (Caputi 
and Giron, 2018).  
 
Studies have been performed where the 
vagus nerve is removed in patients, and the 
development of Parkinson’s is actually 
delayed. This could be an indication of the 
involvement of the vagus nerve in Lewy 
Body transport from ENS to CNS. When the 
vagus nerve is removed from the mice in 
the experiment mentioned above, exposing 
them to rotenone had little effect on the 
development of PD. The symptoms and the 
pathology were drastically delayed. These 
findings may indicate that toxins or other 
environmental factors may play a larger 
role in the development of PD than even 
genetic predisposition. The dysfunction of 
microbiota in the gut may actually be 
enough of a trigger to cause PD 
development – the trigger does not 
necessarily need to be an external factor 
(Caputi and Giron, 2018).  
 
The gut-brain axis is currently being 
pursued as a possible cause for Parkinson’s 
disease. Even if it is found that the cause 
doesn’t lie here, the gut-brain axis still holds 
potential for future treatments and 
therapies for neurodegenerative diseases. A 
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couple of recent studies that have been 
performed are explained below.  
 
Previous Studies 
Due to the degradation of dopaminergic 
neurons in the substantia nigra, an effective 
treatment has been to reintroduce L-DOPA, 
or other dopamine receptor agonists, to the 
patient. The first goal with regards to 
treatment has been to reduce these first 
motor symptoms (Ganjavi and MacDonald, 
2015). One of the problems with this 
method is crossing the blood brain barrier. 
This barrier is designed to protect the brain 
and CNS by limiting what it gets exposed to. 
In order for the L-DOPA to be effective, it 
has needed to be able to access the CNS 
because that is its target area. Also, Dr. 
Lange from the University of the 
Netherlands explains that the only drug that 
has an effect on its target is the free drug – 
it cannot be bound to something.  
 
She also explains that in order to fully know 
a drug’s efficacy, we need to know what it 
does in its unbound form both in the 
plasma as well as at its target in the brain. 
The drug can either be toxic and not 
beneficial, toxic and beneficial, non-toxic 
and not beneficial, or non-toxic and 
beneficial. She and her lab performed a 
study on mice using rotenone, like the one 
mentioned previously. They observed the 
substantia nigra in a control mouse brain, as 
well as mice exposed to the pesticide. They 
wanted to know if the blood brain barrier 
could be weakened and penetrated after 
exposure. They also wanted to observe the 
development of Lewy Bodies.  
 
They wanted to determine what the 
concentration of the drug in human 
cerebral spinal fluid (CSF) would be similar 
to the target concentration, so they 
determined the areas from where they 
would draw CSF from humans as well as the 
mice. They compared brain extracellular 
fluid to CSF by obtaining samples from the 
striatum, lateral ventricles, and cisterna 
magna. They began to predict the ideal 
physiological markers for concentration of 
the CSF in humans and compared that with 
the rodents. Using their animal experiments 
and pharmacokinetic models, they were 
able to predict values in humans, and then 
they finally were able to confirm those 
values in humans (De lange and 
Hammarlund – Udenaes, 2018). 
 
She and her lab explain that one of the 
biggest challenges regarding drug 
development is ensuring the drug crosses 
the BBB “at the right place at the right time, 
and at the right concentration.” It needs to 
be lipophilic enough to be able to travel 
across the barrier, but it needs to be 
lipophobic enough to get a wide 
distribution throughout the brain (De 
Lange, et al., 2017).    
 
 
 
 
 
 
The Role of the Gut-Brain Axis on Neurodegenerative Diseases 7 
 
 
 
 
 
 
 
Figure 2: Dr Lange, et al., demonstrate the 
data they obtained based on their 
predictions above. They were able to 
confirm their predictions (2018).  
 
These results have been beneficial to treat 
patients with Parkinson’s, however, one 
issue that needs to be dealt with involves 
the cyclic patterns of taking L-DOPA. These 
cycles are termed “on-off fluctuations” or 
“wearing off”. The wearing off period 
happens as the drug wears off and loses 
Figure 1: Dr Lange, et al., explains their prediction for BBB penetration and target system 
utilization of L-DOPA in humans (2018).  
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some of its effect and is also due to the 
“pulsatile” pattern of activating the 
dopaminergic neurons. The on-off 
fluctuations involve a more random and 
uncontrolled switch between experiencing 
the typical PD symptoms (similar to a 
relapse) and existing in an almost over 
treated state (similar to a remittance).  
 
The response to these cycles has evolved 
over the years, and now consists of taking 
multiple lower doses instead of one large 
dose. In addition to these lower, more 
frequent doses, a COMT inhibitor, MAO 
inhibitor, and dopamine agonists are also 
utilized. The COMT inhibitor is able to 
prolong the duration and effect of L-DOPA, 
because the COMT enzyme is blocked. As 
with everything, there are some negative 
side effects to this. The buildup of 
dopamine in the synaptic cleft could lead to 
worsening of the psychosis and dementia 
that patients may experience. It has 
become almost standard to decrease the 
amount of dopamine taken by a patient if 
their psychotic state is too high. Clinicians 
will decrease the dose even if that means 
causing the Parkinson’s symptoms to 
worsen (Varanese, et al., 2010).  
 
For a long time, researchers had thought 
that L-DOPA was converted to dopamine in 
the nigrostriatal pathway in the brain by 
“dopaminergic terminals.” This dopamine 
would then travel to the striatum and elicit 
the relief from the motor symptoms that is 
seen. However, it has recently been 
observed that L-DOPA is converted by 
serotonin neurons and released to the 
striatum. These neurons take exogenous L-
DOPA and decarboxylate it to provide the 
effect. Even areas that don’t have 
dopaminergic neurons will have an increase 
in dopamine due to the presence of 5HT 
neurons.  
 
The increase of dopamine in these areas 
can lead to unpleasant side effects, such as 
more motor issues, increased psychosis, 
and depression. Neurotoxicity can occur 
due to the increase of dopamine, and 5HT 
production can decrease. Dopamine can be 
converted to one of its metabolites, and 
this will inhibit the enzyme that converts 
tryptophan in the serotonin pathway.  
These issues were studied in rats by giving 
them L-DOPA for 10 consecutive days and 
observing the concentration of 5HT neurons 
as well as 5HT neurotransmitters. It was 
found that L-DOPA decreased the number 
of 5HT cell bodies as well as the amount of 
neurotransmitters. It caused 5HT to be 
displaced from the vesicles as led to a 
decrease in the concentration of 5HT in 
tissues. Extracellular levels were also 
decreased and there was less dopamine 
released. This led the researchers to believe 
that 5HT neurons are damaged with excess 
L-DOPA because they normally release 
dopamine as well. The Parkinson-like 
symptoms that were seen during treatment 
may actually be due to the imbalance of DA 
and 5HT in the striatum. Also, L-DOPA has 
been found to lose some of its effects the 
longer it is taken. This may be due to the 
fact the dopaminergic receptors continue to 
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deplete due to PD pathology, but it may 
also be due to the fact that L-DOPA is 
harmful to 5HT neurons. More research 
needs to be done in this area to know for 
certain (Stansley and Yamamoto, 2015).  
 
 
Table 1: This table indicates the 
concentration of L-DOPA given per day to 
rats in different conditions. It also displays 
what happened to the serotinergic neurons 
and concentration as the study went on. 
Consistently, 5HT was shown to decrease 
whether that be with the concentration in 
tissues or in the extracellular fluid (Stansley 
and Yamamoto, 2015).  
 
 
 
 
 
 
 
Current Studies 
As mentioned previously, one of the largest 
issues with the current L-DOPA treatment is 
the fluctuating response of taking the drug 
orally. It is currently broken down into 
many small doses taken throughout the day 
in order to avoid the high highs and the low 
lows. This semester, I was able to assist 
with part of a study that was designed to 
make the release of L-DOPA consistent. Drs. 
Mochel, Allenspach, and Kanthasamy 
created this study to work with the gut-
brain axis and wanted to determine if that 
could be utilized to make treatment more 
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constant. If the treatment can become 
constant, the symptoms that occur during 
the on-off fluctuations as well as the 
wearing off phase could be more 
controlled. The anxiety that is present 
during the wearing off phase, when the 
drug concentration is low, is also something 
that they hoped to control.  
 
L-DOPA induced kinesia (LID) is the name 
for the motor system side effects that occur 
when taking L-DOPA. These symptoms are 
due to the excess of dopamine present in 
the body as mentioned above. When L-
DOPA administration and conversion are 
not able to be tightly controlled, more of 
these symptoms may be witnessed.  
 
Knowing that the microbiota in the gut has 
a noticeable effect on the brain and 
neurodegenerative diseases, this was an 
important area to target. They 
hypothesized that getting L-DOPA to be 
released from the gut would lead to a 
steady release. In order to get L-DOPA 
produced consistently, they designed a 
probiotic (E. coli Nissle 1917 strain (EcN)) to 
do it. For approximately one month, the 
dogs were administered a treatment with 
the probiotic. Their blood was drawn and 
their feces were sampled. An endoscopy 
was also performed on each dog at the 
beginning and end of the study to sample 
the endothelium of their GI tract (Mochel, 
Allenspach, and Kathasamy, 2019).  
 
Conclusions 
Parkinson’s disease is the second most 
prevalent neurodegenerative disease. Due 
to the number of people suffering from it, 
many people have dedicated their lives to 
researching it. The exact cause of the 
disease is unknown at this time, however 
much progress is being made to determine 
that. Until recently, the gut brain axis and 
its role in the development of 
neurodegenerative diseases was unknown, 
but now it is a huge point of study among 
researchers.  
 
Even if the gut-brain axis is not the exact 
cause of Parkinson’s disease, it may lead 
researchers to identifying what is the cause. 
For now, the gut-brain axis has provided a 
potential new way to treat Parkinson’s 
disease that would drastically deplete the 
number and severity of symptoms 
associated with the current treatment. The 
drug is not necessarily a new discovery, but 
its delivery via probiotic to the gut is what is 
new and exciting.  
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